Destrastuzumab is an antibody conjugate drug (ADC) targeting HER2 developed jointly by AstraZeneca (AZN.US) and Daiichi Sankyo.
The Zhitong Finance App learned that on January 3, the China Drug Evaluation Center (CDE) official website announced that DS-8201a (destretuzumab, Enhertu), which was jointly declared by AstraZeneca (AstraZeneca, code: AZN.US) and Daiichi Sankyo (Daiichi Sankyo), is intended to be included as a breakthrough treatment. The proposed indications are: adult patients with irreversible or metastatic non-small cell lung cancer patients who have had HER2 (ERBB2) mutations activated and have received at least one systematic treatment in the past.
According to reports, detrustuzumab is an antibody-conjugated drug (ADC) targeting HER2 jointly developed by AstraZeneca and Daiichi Sankyo. At the same time, this is also the third time that this product is intended to be included in the CDE as a breakthrough treatment. In China, the product has previously been approved for the treatment of HER2 positive and HER2 low expression adult breast cancer patients. Furthermore, the product has previously been included by CDE as a breakthrough treatment for HER2 positive breast cancer and HER2 positive gastric or gastroesophageal junction adenocarcinoma, respectively.